echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > Lancet: Safety and Efficacy Study of Aspirin, Unfractionated Heparin During Endovascular Stroke Treatment (MR CLEAN-MED): Increased Risk of Symptomatic Intracranial Hemorrhage, No Evidence of Beneficial Functional Outcomes!

    Lancet: Safety and Efficacy Study of Aspirin, Unfractionated Heparin During Endovascular Stroke Treatment (MR CLEAN-MED): Increased Risk of Symptomatic Intracranial Hemorrhage, No Evidence of Beneficial Functional Outcomes!

    • Last Update: 2022-04-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Following endovascular treatment ofischemic stroke , many patients fail to recover despite rapid and successful angiographic reperfusion due to occlusion of large intracranial vessels in the anterior circulation .
    Perioperative antithrombotic drugs enhance angiography and microvascular recanalization and are frequently used to reduce thrombotic complications .
    However, for aspirin and heparin, it is unclear whether the potential benefits of perioperative use outweigh the possible increased risk of symptomatic intracranial hemorrhage .

    Stroke Vascular Thrombosis However, for aspirin and heparin, it is unclear whether the potential benefits of perioperative use outweigh the possible increased risk of symptomatic intracranial hemorrhage
    .


    Because aspirin increased the risk of developing intracranial hemorrhage in previous trials, guidelines recommend against using aspirin early after intravenous thrombolysis, but there is no evidence of favorable efficacy
    .


    However, in this trial of patients with ischemic stroke who received intravenous thrombolysis before endovascular therapy, the intervention group had a low 4.
    3% risk of symptomatic intracranial hemorrhage


    guide

    In the current study, the Netherlands Multicenter Randomized Clinical Trial of Endovascular Treatment of Acute Ischemic Stroke (MR CLEAN-MED), investigators sought to evaluate the initiation of endovascular therapy with intravenous aspirin, unfractionated heparin, both, or neither.


    Safety and efficacy in patients with ischemic stroke due to anterior circulation large vessel occlusion


    In the current study, the Netherlands Multicenter Randomized Clinical Trial of Endovascular Treatment of Acute Ischemic Stroke (MR CLEAN-MED), investigators sought to evaluate the initiation of endovascular therapy with intravenous aspirin, unfractionated heparin, both, or neither.
    Safety and efficacy in patients with ischemic stroke due to anterior circulation large vessel occlusion


    We conducted an open-label, multicenter, randomized controlled trial with a 2 × 3 factorial design at 15 centers in the Netherlands
    .


    We recruited adult patients (ie, ≥18 years of age) with ischemic stroke due to anterior circulation large vessel occlusion who could initiate endovascular therapy within 6 hours of symptom onset


    An open-label, multicenter, randomized controlled trial investigators enrolled adult patients (ie, ≥18 years of age) with ischemic stroke due to anterior circulation large vessel occlusion who could initiate vascular initiation within 6 hours of symptom onset internal treatment


    • Between January 22, 2018, and January 27, 2021, 663 patients were randomized; 628 (95%) of whom provided deferred consent or died before consent could be requested and were included in modified intention-to-treat crowd
      .


      On February 4, 2021, following unblinding and analysis of the data, the trial steering committee permanently halted patient recruitment and the trial was halted due to safety concerns


      Both perioperative intravenous aspirin and unfractionated heparin during endovascular therapy increased the risk of symptomatic intracranial hemorrhage, but there was no evidence of a beneficial effect on functional outcomes


      van der Steen W, van de Graaf RA, Chalos V, et al.
      Safety and efficacy of aspirin, unfractionated heparin, both, or neither during endovascular stroke treatment (MR CLEAN-MED): an open-label, multicentre, randomised controlled trial .
      Lancet.
      2022;399(10329):1059-1069.
      doi:10.
      1016/S0140-6736(22)00014-9 Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.